Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dimenoxadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.52 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.52 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.51 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.50 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.50 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.47 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.47 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.44 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimenoxadol SCHEMBL2886211 | 1.00 | CYP3A4 (0.70) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Dimenoxadol SCHEMBL5854258 | 0.99 | CYP3A4 (0.69) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Dimenoxadol SCHEMBL25993 | 0.99 | CYP3A4 (0.68) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Dimenoxadol SCHEMBL2204879 | 0.97 | CYP3A4 (0.67) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Dimenoxadol SCHEMBL4580231 | 0.87 | CYP3A4 (0.55) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Denaverine SCHEMBL9569397 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Pargeverine SCHEMBL30728632 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Denaverine SCHEMBL147346 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| Pargeverine SCHEMBL2111437 | 0.84 | CYP3A4 (0.51) | CYP3A4CYP2D6LMNAPOLBALDH1A1 | |
| SCHEMBL27585378 | 0.82 | CYP3A4 (0.63) | CYP3A4CYP2D6LMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858887-B2 | Linker compounds, methods of producing the same and uses thereof | SHENKAR COLLEGE OF ENGINEERING AND DESIGN (IL) | 2024-01-02 | — | — | US | claimed |
| JP-1056660-A | — | — | None | — | — | JP | disclosed |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12522684-B2 | Active-energy-ray-curable resin composition and cured product thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20260007779-A1 | CT CONTRAST AGENT FOR DETECTION OF CACHEXIA | UNIV GENEVE (CH) | 2026-01-08 | — | — | US | disclosed |
| EP-4674238-A1 | HOLE-SELECTIVE CONTACT MATERIAL, PHOTOELECTRIC CONVERSION DEVICE AND POLYCYCLIC AROMATIC HYDROCARBON COMPOUND | Okinawa Institute of Science and Technology School Corporation (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4660176-A1 | N-HETEROCYCLIC COMPOUNDS USED AS NITRIFICATION INHIBITOR | EuroChem Antwerpen (BE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4159779-B1 | ACTIVE-ENERGY-RAY-CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF | NIPPON CATALYTIC CHEM IND (JP) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4630122-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | Aptose Biosciences Inc. (CA) | 2025-10-15 | — | — | EP | disclosed |
| EP-0713134-B1 | Processing method for silver halide photographic light-sensitive material | KONISHIROKU PHOTO IND (JP) | 1997-10-08 | — | — | EP | disclosed |
| US-5618661-A | SUPPORTING BY A STRETCHED STYRENE POLYMER; ANTIFOGGING, NONDEGRADING | KONICA CORPORATION (JP) | 1997-04-08 | — | — | US | disclosed |
| US-5571660-A | Method for forming an image | KONICA CORPORATION (JP) | 1996-11-05 | — | — | US | disclosed |
| US-5527800-A | A 4H-PYRROLO(3,2,1-IJ)QUINOLIN-8-YL DERIVATIVE ADMINISTERED FOR THERAPY OR PROPHYLAXIS OF SENILE DEMENTIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| EP-0713134-A1 | Processing method for silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0642055-A1 | A method of forming an image | KONICA CORPORATION (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0607864-A2 | Tricyclic condensed heterocyclic compounds for the treatment of senile dementic | Takeda Chemical Industries, Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-4965182-A | CYANINE DYES | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-23 | — | — | US | disclosed |
| JP-S6456660-A | UREA DERIVATIVE OR ITS SALT, PRODUCTION THEREOF AND GERMICIDE FOR AGRICULTURE AND HORTICULTURE CONTAINING SAID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | SUMITOMO CHEMICAL CO | 1989-03-03 | — | — | JP | disclosed |
| EP-0301477-A2 | Silver halide color photosensitive material and method of processing thereof | Fuji Photo Film Co., Ltd. (JP) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007779-A1 | CT CONTRAST AGENT FOR DETECTION OF CACHEXIA | CPT1B, PNLIP, CPT1A | CHRM2 812/4885CHRM1 937/4885CHRM3 1006/4885 |
| US-11858887-B2 | Linker compounds, methods of producing the same and uses thereof | PAICS, CA1, ECPAS | CHRM2 2630/4885CHRM1 2471/4885CHRM3 2273/4885 |
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | CAPRIN1, NOS1, NCBP1 | CHRM2 2488/4885CHRM1 1079/4885CHRM3 1527/4885 |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | FLT3, FLT1, ADK | CHRM2 3981/4885CHRM1 4176/4885CHRM3 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.